Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
 
Company Logo
Visit the company website
 

Stock Quote & Recent News Cardiol Therapeutics Inc. T.CRDL

Alternate Symbol(s):  CRDL | T.CRDL.W.A

Healthcare Drug Manufacturers - Major
Cardiol Therapeutics’ lead product, CardiolRx™, is a pharmaceutically produced oral cannabidiol formulation that is currently being evaluated in a Phase II/III multi-national study, the LANCER trial. Cardiol has also received IND authorization from the FDA to conduct clinical studies to evaluate CardiolRx™ in two orphan drug indications: (i) a Phase II multi-national trial in acute myocarditis; and (ii) a Phase II multicenter open-label pilot study in recurrent pericarditis.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (TSX:CRDL)

Fundamentals Snapshot (TSX:CRDL)

"IND clearance to proceed with our Phase II clinical trial of CardiolRx in patients with acute myocarditis represents another major milestone for Cardiol as we continue to pursue the development of new treatment options for patients with inflammatory heart disease. We look forward to further studying the cardioprotective potential of CardiolRx in this rare but potentially devastating condition (acute myocarditis) that remains an underdiagnosed cause of acute heart failure, sudden death, and chronic dilated cardiomyopathy."

Current News (TSX:CRDL)

Cardiol Therapeutics Announces At-The-Market Equity Offering Program

Newsfile June 9, 2022

Market Movers. Today’s Top Stock Picks For New & Trending Opportunities

Stockhouse Editorial June 1, 2022

Market Movers. Today's Top Stock Picks For New & Trending Opportunities

Accesswire May 27, 2022

Cardiol Therapeutics (TSX:CRDL) appoints new directors

Shoran Devi May 19, 2022

Cardiol Therapeutics Appoints Teri Loxam and Chris Waddick to its Board of Directors

Newsfile May 19, 2022

Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-Label Pilot Study of CardiolRx(TM) for Recurrent Pericarditis

Newsfile May 17, 2022
View More News ››

"As our study represents one of the most comprehensive Phase I clinical trials ever conducted in adults with a pharmaceutically produced cannabidiol formulation, we are pleased that the data are consistent with our expectations concerning the drug’s safety, tolerability, and PK profile."

Opinion & Analysis (TSX:CRDL)

No current opinion is available.
View More Opinion ››

"The COVID-19 pandemic is providing our Company with a unique opportunity to rapidly study the cardioprotective properties of CardiolRx in patients who have a prior history of, or risk factors for, cardiovascular disease and are most vulnerable to the virus. Subject to study outcomes, our discussions with the FDA indicated that the design and scope of our Phase II/III trial may be used as a registration study in support of a New Drug Application."

Bullboard Posts (TSX:CRDL)

RE:RE:RE:Geez

Agreed - the $50M looks to be the catalsy for share price drop. Although, as a micro-biotech company I would say this turned out to be a...
TenPennies - June 9, 2022

RE:RE:Im buying the dip

boilerroom stooge ..not letting you work from home ? Lol
ProphetSays - June 7, 2022

RE:Im buying the dip

still Pumping Jordan? I think you said this almost a year and a half ago LOL
Mapleleaf57 - May 20, 2022

Im buying the dip

Nice that we are able to nibble away on some Cardiol stock below $1.75. I think if we all hold here long enough, brighter days will...
Jordan1159 - May 19, 2022

RE:RE:RE:Picked up a few more shares

GW is definately ahead in respect to EPI...cant help but wonder if CRDL gets orphan designation for acute myocarditis, larger addressible...
TenPennies - May 10, 2022

RE:RE:Picked up a few more shares

I can't see this one surviving. CBD is everywhere and GW pharma which produces pharma grade CBD is way ahead of them. Don't...
Bullknit101 - April 30, 2022
View more Bullboard ››

follow t.crdl on

COMPANY OVERVIEW HISTORY LEADERSHIP CARDIOLRXTM PIPELINE EVENTS & PRESENTATION RESEARCH ANALYST REPORTS FILINGS & FINANCIALS STOCK INFORMATION CONTACT

View the Presentation
View the Presentation

Visit the company website

TWITTER

IR CONTACT

Trevor Burns
trevor.burns@cardiolrx.com
+1 (289) 910-0855

Cardiol Therapeutics Inc.
602-2265 Upper Middle Road East
Oakville, ON L6H 0G5